The transition of human embryonic stem cells (hESCs) from pluripotency to lineage commitment is not fully understood, and a role for phenotypic transcription factors in the initial stages of hESC differentiation remains to be explored. From a screen of candidate factors, we found that RUNX1 is selectively and transiently upregulated early in hESC differentiation to mesendodermal lineages. Transcriptome profiling and functional analyses upon RUNX1 depletion established a role for RUNX1 in promoting cell motility. In parallel, we discovered a loss of repression for several epithelial genes, indicating that loss of RUNX1 impaired an epithelial to mesenchymal transition during differentiation. Cell biological and biochemical approaches revealed that RUNX1 depletion specifically compromised TGFB2 signaling. Both the decrease in motility and deregulated epithelial marker expression upon RUNX1 depletion were rescued by reintroduction of TGFB2, but not TGFB1. These findings identify roles for RUNX1-TGFB2 signaling in early events of mesendodermal lineage commitment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106514 | PMC |
| http://dx.doi.org/10.1016/j.stemcr.2016.09.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.
Leukemia
December 2024
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
The transcription factor MYB is frequently upregulated in T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignancy originating from T-cell precursors. Here, we demonstrate that MYB plays a crucial role by regulating genes essential for T-ALL pathogenesis. Integrative analysis reveals a long MYB isoform, ENST00000367814.
View Article and Find Full Text PDFA phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia.
Blood
October 2024
Department of Medical Oncology, West Virginia University School of Medicine, United States.
Glutamine dependency has been shown to be a metabolic vulnerability in acute myeloid leukemia (AML). Prior studies using several in vivo AML models showed that depletion of plasma glutamine induced by the long-acting crisantaspase (pegcrisantaspase or PegC) was synergistic with the BCL-2 inhibitor venetoclax (Ven), resulting in significantly reduced leukemia burden and enhanced survival. Here, we report a phase 1 study (NCT04666649) of Ven and PegC combination (VenPegC) for treating adult patients with relapsed or refractory AML, including patients who had previously received Ven.
View Article and Find Full Text PDFAlternating high-fat diet enhances atherosclerosis by neutrophil reprogramming.
Nature
October 2024
Paris Cardiovascular Research Center, Université Paris Cité, INSERM U970, Paris, France.
Article Synopsis
- Chronic high cholesterol levels lead to systemic immune responses that accelerate atherosclerosis, but the impact of alternating high-fat diets (HFD) had not been well studied.
- Researchers used a mouse model to compare the effects of an alternating HFD versus a continuous HFD on atherosclerosis progression, finding that the alternating diet significantly worsened the condition.
- The study revealed that this worsening was linked to IL-1β production, which triggered inflammatory responses and increased neutrophil levels that contributed to plaque formation and exacerbated atherosclerosis, suggesting that targeting these pathways could reverse the effects.
Identification of epigenetic modifiers essential for growth and survival of AML1/ETO-positive leukemia.
Int J Cancer
December 2024
Department of Hematology/Oncology/Stem Cell Transplantation, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany.
Article Synopsis
- Aberrant gene expression in acute myeloid leukemia (AML) with translocations is linked to the dysregulation of epigenetic modifiers, specifically involving the AML1/ETO fusion protein.
- The study aimed to pinpoint critical epigenetic modifiers essential for the survival and growth of AML1/ETO-positive AML cells through shRNA library screens and transcriptomics.
- Researchers identified and validated 41 essential genes, including DNMT1 and ATR, which can be inhibited by specific drugs, showing potential for effective treatment strategies in AML1/ETO-positive patients.
CD8 T Cells Drive Plaque Smooth Muscle Cell Dedifferentiation in Experimental Atherosclerosis.
Arterioscler Thromb Vasc Biol
August 2024
Institute of Experimental Biomedicine (S.S., M.R., Y.K., L. Beck, J.G., C.C., A.Z.), University Hospital of Würzburg, Germany.
Background: Atherosclerosis is driven by the infiltration of the arterial intima by diverse immune cells and smooth muscle cells (SMCs). CD8 T cells promote lesion growth during atherosclerotic lesion development, but their role in advanced atherosclerosis is less clear. Here, we studied the role of CD8 T cells and their effects on SMCs in established atherosclerosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!